Lecture Notes: Rapamycin and the PEARL Trial

Introduction to Rapamycin

• Rapamycin: A molecule known for inhibiting mTOR, a master protein within cells.
• mTOR: Associated with several diseases and reduced lifespan.
• Potential: Shown promise in non-human studies for longevity effects.

The PEARL Trial Overview

• Purpose: To assess the effects of rapamycin on various health metrics and its safety.
• Participants: 115 men and women completed the study.
• Dosage: Participants were given 5mg, 10mg, or placebo (no rapamycin) once per week for 48 weeks.

Results of the PEARL Trial

• Improvements Noted:
  • Bone Mineral Content: Improvement in the 10mg group.
  • Muscle Mass: Improvement noted in women specifically.
• General Findings:
  • No significant differences across 20+ measurements.
  • Small effect sizes observed.

Interpretation and Challenges

• Primary Focus: The trial was primarily a safety trial.
  • No Serious Adverse Effects: Linked to rapamycin use.
• Study Limitations:
  • Power Calculation: Difficult due to limited prior human data.
  • Dosage Issue: Due to a packaging error, doses were about 30% of intended levels.
• Data Interpretation:
  • Some individuals showed positive responses.
  • Dr. Kaeberlein mentioned body composition improvements as a point of interest.
  • General consensus: Study fails to show strong effects.

Future Directions

• Safety Confirmed: At low doses, rapamycin is likely safe.
• Need for Further Studies: A need to conduct studies with effective doses.
  • Challenges: Lack of funding and support for large-scale trials.

Conclusion

• Ongoing Frustration: Need for more definitive trials.
• Funding Issues: Call for funders to support additional trials.

---

• 📊 The PEARL trial assessed the effects of rapamycin on health metrics, revealing conflicting results compared to previous studies.
• 🔍 Participants included 115 individuals, receiving varying doses of rapamycin or placebo over 48 weeks.
• 🦴 Improvements were noted in bone mineral content and muscle mass, but most other health measures showed no significant changes.
• 🚫 The primary aim of the study was safety, limiting its ability to measure broader effects and secondary outcomes.
• ⚠️ Actual doses administered were around 30% of the intended amounts due to packaging errors, which may have impacted results.
• 💊 Despite small effect sizes, the study suggests that low doses of rapamycin are likely safe for healthy individuals.
• 🔄 Further studies with appropriate dosing are necessary to better understand rapamycin's potential benefits.
• 💰 Funding and support for larger trials are critical to advance research on rapamycin and its longevity effects.